These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28819961)

  • 1. [Bioresorbable scaffolds in the treatment of coronary artery disease. Expert consensus statement of the Association of Cardiovascular Interventions of the Polish Cardiac Society (ACVI PCS)].
    Reczuch K; Milewski K; Wąsek W; Rzeszutko Ł; Wojakowski W; Hawranek M; Włodarczak A; Pawłowski T; Kochman J; Dobrzycki S; Grygier M; Ochała A; Wójcik J; Lesiak M; Dudek D; Legutko J
    Kardiol Pol; 2017; 75(8):817-835. PubMed ID: 28819961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioresorbable vascular scaffolds: From patient selection to optimal scaffold implantation; tips and tricks to minimize device failure.
    Tanaka A; Jabbour RJ; Latib A; Colombo A
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):10-20. PubMed ID: 27797460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Percutaneous coronary intervention: balloons, stents and scaffolds.
    Colleran R; Kastrati A
    Clin Res Cardiol; 2018 Aug; 107(Suppl 2):55-63. PubMed ID: 30039189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioresorbable vascular scaffolds in left main coronary artery disease.
    Everaert B; Capranzano P; Tamburino C; Seth A; van Geuns RJ
    EuroIntervention; 2015; 11 Suppl V():V135-8. PubMed ID: 25983148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paving the way to a bioresorbable technology: Development of the absorb BRS program.
    Perkins LE; Kossuth MB; Fox JC; Rapoza RJ
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):1-9. PubMed ID: 27797462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design Principles of Bioresorbable Polymeric Scaffolds.
    Kossuth MB; Perkins LEL; Rapoza RJ
    Interv Cardiol Clin; 2016 Jul; 5(3):349-355. PubMed ID: 28582032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of bioresorbable scaffolds in the treatment of coronary artery disease.
    Wiebe J; Nef HM; Hamm CW
    J Am Coll Cardiol; 2014 Dec; 64(23):2541-51. PubMed ID: 25500240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: Clinical outcomes from randomized controlled trials.
    Rizik DG; Hermiller JB; Kereiakes DJ
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):21-30. PubMed ID: 27797464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of bioresorbable vascular scaffold Absorb BVS® in patients with stable coronary artery disease: one-year results with special focus on the hybrid bioresorbable vascular scaffolds and drug eluting stents treatment.
    Gil RJ; Bil J; Pawłowski T; Yuldashev N; Kołakowski L; Jańczak J; Jabłoński W; Paliński P
    Kardiol Pol; 2016; 74(7):627-33. PubMed ID: 26779846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioresorbable Scaffold With Drug-Coated Balloon: A "Biodegradable" Model for Bifurcation Lesions Treatment. The New Intriguing Chapter of the "Leaving Nothing Behind" Saga.
    Buccheri D; Piraino D; Andolina G
    Am J Cardiol; 2016 Jul; 118(2):308-9. PubMed ID: 27206913
    [No Abstract]   [Full Text] [Related]  

  • 11. No more metallic cages: an attractive hybrid strategy with bioresorbable vascular scaffold and drug-eluting balloon for diffuse or tandem lesions in the same vessel.
    Naganuma T; Latib A; Ielasi A; Panoulas VF; Sato K; Miyazaki T; Colombo A
    Int J Cardiol; 2014 Apr; 172(3):618-9. PubMed ID: 24495653
    [No Abstract]   [Full Text] [Related]  

  • 12. Bioresorbable vascular scaffold in patients with complex coronary artery disease.
    Tamburino CI; Capranzano P; Longo G; Immè S; Tamburino G; Scalia M; Condorelli A; Francaviglia B; LA Manna A; Sgroi C; Grasso C; DI Salvo ME; Capodanno D; Tamburino C
    Minerva Cardioangiol; 2016 Aug; 64(4):481-6. PubMed ID: 27128353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bioresorbable Vascular Scaffold: A Focused Review on Development and Preclinical Studies].
    Ke L; Huang Y; Liu L; Duan X; Feng X; Wang C
    Zhongguo Yi Liao Qi Xie Za Zhi; 2018 Feb; 42(2):115-118. PubMed ID: 29845812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioresorbable metal scaffold for cardiovascular application: current knowledge and future perspectives.
    Kitabata H; Waksman R; Warnack B
    Cardiovasc Revasc Med; 2014 Mar; 15(2):109-16. PubMed ID: 24684760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome After Long-segment Stenting With Everolimus-eluting Bioresorbable Scaffolds Focusing on the Concept of Overlapping Implantation.
    Wiebe J; Dörr O; Liebetrau C; Bauer T; Wilkens E; Ilstad H; Boeder N; Elsässer A; Möllmann H; Hamm CW; Nef HM
    Rev Esp Cardiol (Engl Ed); 2016 Dec; 69(12):1144-1151. PubMed ID: 28134094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [SICI-GISE Position paper: Use of Absorb BVS in clinical practice].
    Tarantini G; Saia F; Capranzano P; Cortese B; Mojoli M; Boccuzzi G; Cuculo A; Geraci S; Mattesini A; Oreglia J; Summaria F; Testa L; Berti S; Esposito G; La Manna A; Limbruno U; Marchese A; Mauro C; Tarantino F; Salvi A; Santoro G; Varbella F; Violini R; Musumeci G
    G Ital Cardiol (Rome); 2016 Oct; 17(10 Suppl 1):28S-44. PubMed ID: 27729667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current status of drug-eluting stents and drug-eluting balloons in patients with stable coronary artery disease--an expert consensus document of the Association for Percutaneous Cardiovascular Interventions and Polish Cardiac Society].
    Witkowski A; Opolski MP; Dudek D; Lesiak M; Legutko J; Wojakowski W; Ochała A; Maciejewski P; Deptuch T; Araszkiewicz A; Gil R; Grajek S; Poloński L;
    Kardiol Pol; 2011; 69 Suppl 1():1-38. PubMed ID: 22125234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The unmet needs: How future technologies will address current limitations of bioresorbable scaffold technology.
    Abizaid A; Ribamar Costa J
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):54-59. PubMed ID: 27797459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of coronary bifurcation lesions: current knowledge and future perspectives.
    Elwany M; Palma GD; Cortese B
    Future Cardiol; 2018 Mar; 14(2):165-179. PubMed ID: 29372810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.